Opportunity brief · SAM.gov combined synopsis/solicitation

NOI - DNA Sequencing of Bone Marrow Failure Syndro

Health and Human Services, Department of · National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO · Solicitation 75N98027Q00027 · NAICS 325413 In-Vitro Diagnostic Substance Manufacturing · offers due 2026-11-02 · Open on SAM.gov ↗

Posted
2026-10-22
Product or service code
6550 · In Vitro Diagnostic Substances, Reagents, Test Kits and Sets
Likely size
$252.6K – $252.6K

Putting the brief together: the incumbent, who else wins this work, the contracting office and past prices…

From the notice

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00027. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Integrated DNA Technologies, Inc. (IDT), 1710 Commercial Park, Coralville, IA 52241, for custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits. Integrated DNA Technologies, Inc.

Read the whole notice and its files on SAM.gov ↗

More open In-Vitro Diagnostic Substance Manufacturing contract opportunities

Who wins In-Vitro Diagnostic Substance Manufacturing contracts

FAR and DFARS clauses this notice cites

  • FAR 12.603 · Streamlined solicitation for commercial products or commercial services
  • FAR 6.302-3 · Industrial mobilization; engineering, developmental, or research capability; or expert services

All 10 open notices in NAICS 325413 · In-Vitro Diagnostic Substance Manufacturing: who buys it and who wins it · Contracts in this industry coming up for re-bid · The contracting office · Health and Human Services, Department of: spending and contractors · How big In-Vitro Diagnostic Substance Manufacturing contracts usually are ·